“Global Checkpoint Inhibitors for Anti-Cancer Treatment market set to grow to $22bn by 2024” says Visiongain report

28 May 2019
Pharma

Visiongain has launched a new pharma report Checkpoint Inhibitors for Anti-Cancer Treatment Market Report : CTLA-4 Inhibitors, PD-1 Inhibitors, 3 PD-L1 Inhibitors, Ipilimumab, Nivolumab, Pembrolizumab, Pipeline Drugs.

Checkpoint inhibitors have changed the landscape of melanoma treatment in the last few years and advanced it in ways that could not have been possible before. The response rates achieved and survival rates are so much higher than any seen before and metastatic melanoma patients are living much longer. The global checkpoint inhibitor for anti-cancer treatment market is estimated to have reached $11.43 bn in 2018 and is expected to grow at a CAGR of 13.7% during the forecast period.

The lead analyst of the report commented "One opportunity for driving growth in the checkpoint inhibitor market is the development of companion diagnostic tests. These tests would be indispensable as they would allow treatment to be given only to those patients who would derive the most benefit from it and not add to the cost burden by eliminating patients who would gain no advantage from using this treatment or would be susceptible to severe side effects such as autoimmune-related effects."

Leading companies featured in the report include AstraZeneca, Plc, Bristol-Myers Squibb Co., Celldex Therapeutics, Inc., Incyte Corporation, Merck & Co., Inc, Novartis, Pfizer, Roche and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Clinical Trial Supplies Market Report 2021-2031

Deviating from protocols raises the danger of missing or delaying data collection from current investigations. This highlights the growing importance of digital medicine, which is being aided by advancements in cloud, mobile, and IoT technology.

11 October 2021

Read

Visiongain Publishes Drug Discovery Informatics Market Report 2021-2031

High performance HPC and supercomputing technology have evolved substantially in China in the last decades, leading to extraordinary accomplishments. HPC-based and combined pharmaceutical chemical and computational biology computational discovery and design has become a significant technique in drug research and development and is sponsored financially by the Chinese government.

07 October 2021

Read

Visiongain Publishes Pharma Wholesale and Distribution Market Report 2021-2031

Many health-care organizations are seeing organic growth at levels that their supply networks were never designed to handle. Others are frantically attempting to integrate diverse technology and procedures as part of a consolidation effort.

06 October 2021

Read

Visiongain Publishes Meningococcal Vaccines Market Report 2021-2031

Rise in prevalence of meningitis, increasing initiatives by government and regulatory authorities coupled strong funding support from non-profit organizations is expected to drive the global meningococcal vaccines market

05 October 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever